403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
Briacell Therapeutics Corp.
(MENAFN- Baystreet) 10:47 AM EST - BriaCell Therapeutics Corp.: Announces that the independent Data Safety Monitoring Board (DSMB) has issued its seventh consecutive positive recommendation following review of clinical data from BriaCell's pivotal Phase 3 Bria-ABC study of Bria-IMT plus immune checkpoint inhibitor (CPI) in patients with metastatic breast cancer. BriaCell Therapeutics Corp.
shares T are trading up $0.02 at $5.06.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment